1-3 of 3
Asa Rangert-Derolf, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden

Emma Hernlund, PhD, Josefine Redig, MSc, Åsa Rangert Derolf, MD PhD, Bjorn Paulsson, MD, Martin Höglund, MD PhD, Simona Vertuani, PhD, Gunnar Juliusson, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2154.
https://doi.org/10.1182/blood-2019-127957
Published: 2019
Journal Articles

Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013

Gunnar Juliusson, MD PhD, Vladimir Lazarevic, MD, Sören Lehmann, MD PhD, Åsa Rangert Derolf, MD PhD, Lars Möllgård, MDPhD, Hege Garelius, MD, Lovisa Wennström, MD PhD, Bertil Uggla, MD PhD, Petar Antunovic, MD, Kristina Myhr-Eriksson, MD, Anders Wahlin, MD PhD, Martin Höglund, MDPhD
Journal: Blood
Blood (2014) 124 (21): 2269.
https://doi.org/10.1182/blood.V124.21.2269.2269
Published: 2014
Journal Articles

Patterns of Expression of CD15, CD33, CD34 and HLA-DR Predict Prognosis in Patients with AML.

Asa Rangert-Derolf, MD, Elisabet Bjorklund, PhD, Joanna Mazur, PhD, Magnus Bjorkholm, Anna Porwit-MacDonald
Journal: Blood
Blood (2004) 104 (11): 3007.
https://doi.org/10.1182/blood.V104.11.3007.3007
Published: 2004